DIAGNOS Inc. (CVE:ADK – Get Free Report)’s share price reached a new 52-week high on Monday . The stock traded as high as C$0.53 and last traded at C$0.48, with a volume of 253755 shares traded. The stock had previously closed at C$0.45.
DIAGNOS Stock Down 3.9%
The company has a market cap of C$59.31 million, a PE ratio of -12.25 and a beta of 0.50. The stock has a 50-day moving average of C$0.36 and a 200-day moving average of C$0.28. The company has a quick ratio of 0.68, a current ratio of 1.49 and a debt-to-equity ratio of 204.05.
Insider Buying and Selling at DIAGNOS
In other DIAGNOS news, Director Robert Dunn purchased 105,000 shares of the stock in a transaction on Friday, August 28th. The shares were purchased at an average price of C$0.48 per share, with a total value of C$50,400.00. Following the acquisition, the director directly owned 2,679,920 shares in the company, valued at approximately C$1,286,361.60. The trade was a 4.08% increase in their position. Over the last 90 days, insiders bought 433,571 shares of company stock valued at $146,400. Company insiders own 16.81% of the company’s stock.
About DIAGNOS
DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Featured Articles
- Five stocks we like better than DIAGNOS
- 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
